Clinical Trials Search | Clareo Health

RECRUITINGPhase 3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Primary Generalized Tonic-Clonic Seizures

Xenon Pharmaceuticals Inc.160 participantsStarted Feb 2023

Mobile, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +135 more locations

COMPLETEDPhase 4

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129

This study will assess the retention rate of perampanel when given as monotherapy or first adjunctive therapy in participants with partial-onset seizures or primary generalized tonic clonic seizures. The study consists of 4 periods: a Screening Period (to start no earlier than 6 weeks before the first dose of study drug), a Titration Period (up to 13 weeks), a Maintenance Period (39 weeks), and a Follow-Up Period (4 weeks).

Partial Onset SeizuresSecondarily Generalized SeizuresPrimary Generalized Tonic-Clonic Seizures

Eisai Inc.54 participantsStarted Aug 2017

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +21 more locations

COMPLETED

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy

NCT02736162

The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.

EpilepsyPartial-Onset SeizuresPrimary Generalized Tonic-Clonic Seizures

Eisai Inc.61 participantsStarted Apr 2016

Filters

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy